Thursday, July 18, 2019 2:59:49 PM
The company has a limited financial ability.
They cant get financing because they arent current, which they are currently attempting to get current.
Getting current will give them options for financing.
What i really like about this company is that they arent wasting money by paying for literally anything at this moment.
No employees (Limited Basis Chris Lowe)
No office space
No overhead
All board members are working/studying at other facilities:
https://www.investing.businessweek.wallst.com/research/stocks/people/board.asp?ticker=NSPX
They own the drug Patents.
The are letting others help in the study and advancement through University/Government Grants. Anything they come up with is owned under the Patents
They are not throwing money away.
No money wasted on PR's.
They only information coming out about their Orphan Status DRUG $MIPSAGARGIN is PUBLISHED via FACTUAL PIER REVIEWED Scientific Communities.
When they solve the Synthesized Mipsagargin hold up and are able to commercially provide a viable supply chain that is going to be the catalyst for PHASE 3 Clinical Trials!
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM